Free Republic
Browse · Search
News/Activism
Topics · Post Article

Skip to comments.

Gilead Sciences (GILD): Analyst Comments on Letter from Democratic Leaders
streetinsider.com ^ | 3/21/2014

Posted on 03/21/2014 10:35:27 AM PDT by RoosterRedux

Gilead Sciences (NASDAQ: GILD) declined on Friday after Democratic leaders request a briefing by Gilead on Hepatitis C drug pricing Link Here. Analyst Robyn Karnauskas of Deutsche Bank spoke to management about the letter, which discusses concerns around an affordability. The company noted that these types of letters have happened from time to time in HIV.

"Rep Waxman has been very vocal around drugs during his tenure. However, this letter is also written from the minority party in Congress currently. Generally, we think that not much comes out of these briefs..."

(Excerpt) Read more at streetinsider.com ...


TOPICS: News/Current Events
KEYWORDS:
This is what has clobbered the biotech stocks and etf's today.
1 posted on 03/21/2014 10:35:27 AM PDT by RoosterRedux
[ Post Reply | Private Reply | View Replies]

To: All
This is the drug in question...
A new pill to treat hepatitis C raises difficult questions about fair pricing, not only in the United States and other affluent nations but in developing countries around the world. Hepatitis C, which afflicts some 150 million people globally, often without symptoms for years, can cause fatigue and fever, cirrhosis or liver cancer.

The pill, known as Sovaldi, or generically as sofosbuvir, costs $84,000 for a standard 12-week course of treatment. That breaks down to $1,000 for each pill, taken daily. The manufacturer, California-based Gilead Sciences, says private insurers are already covering Sovaldi. The question is whether insurers and public programs like Medicare and Medicaid should have to pay so much for this drug, driving up costs for taxpayers and private policyholders.

Gilead says the price is consistent with the cost of previous treatment regimens (a contention disputed by independent experts) and is reasonable given that the drug can have fewer side effects and cures a higher percentage of patients compared with other drugs. In the long run, the company claims, Sovaldi could save money for insurers by preventing patients from getting sicker and needing costly medical care.

Source: http://www.nytimes.com/2014/03/16/opinion/sunday/how-much-should-hepatitis-c-treatment-cost.html?ref=gileadsciencesinc&_r=0


2 posted on 03/21/2014 10:42:52 AM PDT by RoosterRedux (The only true wisdom is in knowing you know nothing -- Socrates)
[ Post Reply | Private Reply | To 1 | View Replies]

To: RoosterRedux
Nostrildamas has been a pox on the U.S. for forty years. He's finally retiring thank God. Vain and nasty parting shot at a good company with a great new drug.

B*st*rd probably shorted the stock before his letter was intentionally released to the public .....

3 posted on 03/21/2014 11:14:14 AM PDT by Servant of the Cross (the Truth will set you free)
[ Post Reply | Private Reply | To 1 | View Replies]

To: RoosterRedux

Since when is what price a private business charges of political concern? When government is trying to impose fascism.


4 posted on 03/21/2014 12:12:27 PM PDT by theBuckwheat
[ Post Reply | Private Reply | To 1 | View Replies]

Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.

Free Republic
Browse · Search
News/Activism
Topics · Post Article

FreeRepublic, LLC, PO BOX 9771, FRESNO, CA 93794
FreeRepublic.com is powered by software copyright 2000-2008 John Robinson